인유두종 바이러스(HPV) 검사 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 제품별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Human Papilloma Virus Testing Market Size, Share, & Trends Analysis Report By Application (Cervical Cancer Screening, Vaginal Cancer Screening), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

시장 규모와 동향

인유두종 바이러스(HPV) 검사 세계 시장 규모는 2024년에 17억 6,000만 달러로 평가되었으며 자궁 경부암과 인두암 등 HPV 관련 암에 대한 인식이 높아짐에 따라 2025-2030년에 걸쳐 CAGR 13.6%로 성장할 것으로 예측됩니다.

교육 활동과 공중 보건 캠페인을 통해 정기적으로 검사를 받는 것이 좋습니다.

가정용 검사 키트의 채용이 시장 확대를 더욱 뒷받침하고 있습니다. 이 키트는 개인이 HPV를 검사하는 데 편리하고, 개인적이고, 이용하기 쉬운 방법을 제공해, 이용자가 보다 적극적으로 건강을 관리할 수 있게 합니다.

예방 건강 관리에 대한 수요 증가는 HPV 검사 산업의 성장을 가속할 것으로 예상되며 HPV 관련 암을 피하기 위해 조기 발견을 요구하는 개인이 증가하고 있습니다. 엔싱법을 포함한 검사법의 기술적 진보는 HPV 검사의 정확성과 효율을 한층 더 높여주고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 인유두종 바이러스(HPV) 검사 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련, 보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 인유두종 바이러스(HPV) 검사 시장 분석 도구
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 인유두종 바이러스(HPV) 검사 시장 : 용도별, 추정 및 예측 분석

• 용도 부문 대시보드
• 인유두종 바이러스(HPV) 검사 시장 : 용도 변동 분석
• 세계의 인유두종 바이러스(HPV) 검사 시장 규모와 동향 분석(용도별, 2018-2030년)
• 자궁 경부암 검진
• 질암 검진

제5장 인유두종 바이러스(HPV) 검사 시장 : 제품별, 추정 및 예측 분석

• 제품 부문 대시보드
• 인유두종 바이러스(HPV) 검사 시장 : 제품 변동 분석
• 세계의 인유두종 바이러스(HPV) 검사 시장 규모와 동향 분석(제품별, 2018-2030년)
• 기기
• 소모품
• 서비스

제6장 인유두종 바이러스(HPV) 검사 시장 : 기술별, 추정 및 예측 분석

• 기술 부문 대시보드
• 인유두종 바이러스(HPV) 검사 시장 : 기술 변동 분석
• 세계의 인유두종 바이러스(HPV) 검사 시장 규모와 동향 분석(기술별, 2018-2030년)
• PCR
• 면역진단
• 기타

제7장 인유두종 바이러스(HPV) 검사 시장 : 최종 용도별, 추정 및 예측 분석

• 최종 용도 부문 대시보드
• 인유두종 바이러스(HPV) 검사 시장 : 최종 용도 변동 분석
• 세계의 인유두종 바이러스(HPV) 검사 시장 규모와 동향 분석(최종 용도별, 2018-2030년)
• 병원 및 클리닉
• 실험실
• 기타

제8장 인유두종 바이러스(HPV) 검사 시장 :지역별, 추정 및 예측 분석

• 지역별 시장 대시보드
• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 인유두종 바이러스(HPV) 검사 시장 : 주요 포인트
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업 히트맵 분석, 2024년
• 기업 프로파일
  • Abbott
  • Biomedical Diagnostics
  • bioMerieux
  • CanAg Diagnostics(Beijing) Co., Ltd.
  • Cemines
  • Bio-Rad Laboratories, Inc.
  • Epigenomics AG
  • Fujirebio
  • Guided Therapeutics, Inc.
  • Oncolab
  • Hologic, Inc.
  • Qiagen
  • Radiant Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG

SHW

영문 목차

영문목차

Market Size & Trends:

The global human papilloma virus testing market size was valued at USD 1.76 billion in 2024 and is expected to grow at a CAGR of 13.6% from 2025 to 2030, attributed to increasing awareness of HPV-related cancers, such as cervical and throat cancers. Educational initiatives and public health campaigns encourage people to get tested regularly, leading to higher screening rates.

The adoption of at-home testing kits is further driving market expansion. These kits provide a convenient, private, and accessible method for individuals to test for HPV, empowering users to manage their health more proactively. The combination of heightened awareness and the availability of at-home testing is significantly boosting market demand.

Rising demand for preventive healthcare is projected to fuel the growth of the HPV testing industry, with more individuals seeking early detection to avoid HPV-related cancers. This shift toward proactive health measures encourages routine HPV screenings, especially for women over 30. Technological advancements in testing methods, including PCR-based and next-generation sequencing, are further enhancing the accuracy and efficiency of HPV tests. These innovations make testing more accessible, reliable, and cost-effective, thus driving market expansion by improving the overall patient experience and encouraging broader adoption of HPV testing solutions.

Global Human Papilloma Virus Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global human papilloma virus (HPV) testing market report on the basis of application, product, technology, end use, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Cervical Cancer Screening
• Vaginal Cancer Screening
• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Instruments
• Consumables
• Services
• Technology Outlook (Revenue, USD Million, 2018 - 2030)
• PCR
• Immunodiagnostics
• Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals & Clinics
• Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Product
  • 1.2.3. Technology
  • 1.2.4. End Use
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application Outlook
  • 2.2.2. Product Outlook
  • 2.2.3. Technology Outlook
  • 2.2.4. End Use Outlook
  • 2.2.5. Regional Outlook
• 2.3. Competitive Scenario

Chapter 3. Human Papilloma Virus (HPV) Testing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Human Papilloma Virus (HPV) Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Human Papilloma Virus (HPV) Testing Market: Application Estimates & Trend Analysis

• 4.1. Application Segment Dashboard
• 4.2. Human Papilloma Virus (HPV) Testing Market: Application Movement Analysis
• 4.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Application, 2018 to 2030 (USD Million)
• 4.4. Cervical Cancer Screening
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Vaginal Cancer Screening
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Human Papilloma Virus (HPV) Testing Market: Product Estimates & Trend Analysis

• 5.1. Product Segment Dashboard
• 5.2. Human Papilloma Virus (HPV) Testing Market: Product Movement Analysis
• 5.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
• 5.4. Instruments
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Consumables
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Services
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Human Papilloma Virus (HPV) Testing Market: Technology Estimates & Trend Analysis

• 6.1. Technology Segment Dashboard
• 6.2. Human Papilloma Virus (HPV) Testing Market: Technology Movement Analysis
• 6.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Technology, 2018 to 2030 (USD Million)
• 6.4. PCR
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Immunodiagnostics
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Human Papilloma Virus (HPV) Testing Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Human Papilloma Virus (HPV) Testing Market: End Use Movement Analysis
• 7.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals & Clinics
  • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.5. Laboratories
  • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Human Papilloma Virus (HPV) Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2030
• 8.3. Human Papilloma Virus (HPV) Testing Market by Region: Key Takeaways
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key Country Dynamics
    • 8.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 8.4.1.3. Competitive Scenario
    • 8.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Germany
    • 8.5.1.1. Key Country Dynamics
    • 8.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.1.3. Competitive Scenario
    • 8.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.2. U.K.
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.5.3. Competitive Scenario
    • 8.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Denmark
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.6.3. Competitive Scenario
    • 8.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.7.3. Competitive Scenario
    • 8.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Norway
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.8.3. Competitive Scenario
    • 8.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key Country Dynamics
    • 8.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.1.3. Competitive Scenario
    • 8.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.4. South Korea
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.7.2.3. Competitive Scenario
    • 8.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 8.7.3.3. Competitive Scenario
    • 8.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.8.2.3. Competitive Scenario
    • 8.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 8.8.3.3. Competitive Scenario
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 8.8.4.3. Competitive Scenario
    • 8.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework/ Reimbursement Structure
    • 8.8.5.3. Competitive Scenario
    • 8.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/ Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key Company Heat Map Analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Abbott
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Biomedical Diagnostics
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. bioMerieux
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. CanAg Diagnostics (Beijing) Co., Ltd.
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Cemines
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Bio-Rad Laboratories, Inc.
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Epigenomics AG
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Fujirebio
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Guided Therapeutics, Inc.
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Oncolab
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. Hologic, Inc.
    • 9.4.11.1. Company Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Strategic Initiatives
  • 9.4.12. Qiagen
    • 9.4.12.1. Company Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Strategic Initiatives
  • 9.4.13. Radiant Pharmaceuticals Limited
    • 9.4.13.1. Company Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Strategic Initiatives
  • 9.4.14. F. Hoffmann-La Roche Ltd
    • 9.4.14.1. Company Overview
    • 9.4.14.2. Financial Performance
    • 9.4.14.3. Product Benchmarking
    • 9.4.14.4. Strategic Initiatives
  • 9.4.15. Siemens Healthineers AG
    • 9.4.15.1. Company Overview
    • 9.4.15.2. Financial Performance
    • 9.4.15.3. Product Benchmarking
    • 9.4.15.4. Strategic Initiatives

관련자료